Conjunctival microcysts density increases after canaloplasty

Article

Conjunctival microcysts density and surface area increases after canaloplasty in glaucomatous eyes.

Conjunctival microcysts density and surface area increases after canaloplasty in glaucomatous eyes, according to an investigation in the British Journal of Ophthalmology.

A team led by Dr Luca Agnifili, Department of Medicine and Ageing Science, Ophthalmic Clinic, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy, looked at 30 consecutive glaucomatous patients. Successful canaloplasty was completed if preoperative intraocular pressure (IOP) was reduced by a third.

Confocal laser-scanning microscopy was used to examine the conjunctiva one week before and 12 weeks after surgery. Outcome measures included the mean density and mean area of the conjunctival microcysts and IOP. Postoperative trabecular distension and scleral modifications were assessed using anterior segment optical coherence tomography.

Twelve weeks postoperatively, canaloplasty was successfully completed in 23 patients (Group 1) but unsuccessful in seven patients (Group 2). IOP was measured at 28.1+/-2.98 and 28.3+/-2.81 mm Hg for groups 1 and 2, respectively. Baseline IOP was 28.1+/-2.98 and 28.3+/-2.81 mm Hg, MMD was 10.61+/-4.31 and 11.35+/-5.6 and MMA was 2845.02+/-411.85 and 2700.56+/-518.85 in groups 1 and 2, respectively.

It was found that density and surface area of the conjunctival microcysts were increased. The aqueous humour filtration across the sclera and conjunctiva were enhanced after canaloplasty.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.